Bernstein cuts Boston Scientific stock target from USD 60 to USD 54
Published on 10/06/2026 at 17:04 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Boston Scientific (ISIN US1011371077) stock last stood at EUR 38.06 on Tradegate on October 6, 2026 at 12:43 p.m. CEST, while Investing.com reported that Bernstein cut its target from USD 60.00 to USD 54.00 on October 5, 2026 and kept an Outperform rating. The Tradegate quote was plus 0.77 percent versus the prior close of EUR 37.77.
Bernstein flags device competition
Bernstein's target cut puts Boston Scientific's Watchman franchise at the center of the valuation debate. According to Investing.com, the firm cited Abbott Laboratories' Amulet 360 device as a competitive threat that could take market share from Watchman.
The same report said Bernstein felt better about Boston Scientific's electrophysiology business but worse about Watchman. That split matters because the target fell by USD 6.00, or 10.00 percent, while the rating remained Outperform.
Cyberattack resets 2026 outlook
The operational risk is broader than device competition. Reuters reported on September 8, 2026 that Boston Scientific expected to miss its previously issued third-quarter and full-year 2026 sales and adjusted profit forecasts after a cybersecurity incident disrupted manufacturing and shipments.
Before the incident, the company had forecast adjusted earnings per share of USD 3.28 to USD 3.32 for full-year 2026 and USD 0.80 to USD 0.82 for the third quarter, according to Reuters. The company plans to provide an updated outlook with its third-quarter results on October 28, 2026.
Second-quarter growth offers a counterweight
Boston Scientific entered the disruption with measurable operating momentum. MarketBeat reported second-quarter 2026 revenue of USD 5.44 billion, up 7.50 percent from the prior-year quarter, while earnings per share reached USD 0.86 versus a USD 0.83 consensus estimate.
The quarterly comparison shows why the October update is important: the business was growing before the cyberattack, but the recovery now has to offset a quantified operational interruption. Boston Scientific also authorized a USD 5.00 billion share-repurchase plan in May 2026, according to MarketBeat.
Tradegate quote stays above yearly low
Boston Scientific's primary listing is on the NYSE, where BSX was last at USD 42.44 on October 6, 2026 at 11:03 a.m. ET, against a 52-week range of USD 41.94 to USD 105.65. The market capitalization was USD 63.1 billion on October 6, 2026.
Price source: substitute price Tradegate, Lang & Schwarz without data set.
Boston Scientific stock facts
- Company: Boston Scientific Corporation
- ISIN: US1011371077
- Ticker: BSX
- Primary exchange: NYSE
- Price Tradegate as of October 6, 2026, 12:43 p.m. CEST: EUR 38.06
- Change versus prior close: plus 0.77 percent
- Prior close Tradegate October 5, 2026: EUR 37.77
- Market capitalization: USD 63.1 billion as of October 6, 2026
- 52-week range: USD 41.94-105.65 as of October 6, 2026
- Sector / Industry: Healthcare / Healthcare Equipment and Supplies
